Loading
EB
Enzo Biochem Inc Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Wolf James G., was filed 13 Feb 2023.
Enzo Biochem Inc: what insiders have been doing
Enzo Biochem Inc belongs to the Healthcare & Pharma sector. Filings by its managers are published through SEC (Form 4). Nothing new has been filed by managers of Enzo Biochem Inc in twelve months, the latest record being from 20 August 2025.
Since 2016, the database holds 28 purchases and 21 sales by insiders of the company.
Elsewhere in the same sector, our signals recently picked up insider purchases at Xenon Pharmaceuticals Inc. and Vivos Inc. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
115
Thresholds
n/a
Buy Volume
€3M
28 ops. · all time
Sell Volume
€4M
21 ops. · all time
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2024FY ended July 2024 · cache
Income statement
RevenueUS$27.5M
Net income-US$22.5M-81.7% margin
Last declaration on 20 August 2025
Declarations115 total
130,000 sharesCommon StockSEC:0001213900-25-078738:1
40,000 sharesCommon StockSEC:0001213900-25-078738:2
15,000 sharesCommon StockSEC:0001213900-25-078738:3
277,237 sharesCommon StockSEC:0001213900-25-078738:4
430,000 sharesCommon StockSEC:0001213900-25-078744:1
45,065 sharesCommon StockSEC:0001213900-25-078737:1
4,533,779 sharesCommon StockSEC:0001213900-25-078744:0
239,992 sharesCommon StockSEC:0001213900-25-078741:0
28,328 sharesCommon StockSEC:0001213900-25-078740:0
142,897 sharesCommon StockSEC:0001213900-25-078738:0
359,737 sharesCommon StockSEC:0001213900-25-078737:0
142,897 shares0Common StockSEC:0001213900-25-004653:0
142,897 shares0Common StockSEC:0001213900-25-004656:0
142,897 shares0Common StockSEC:0001213900-25-004655:0
70,885 shares@ US$1.1792.7% of flowCommon StockSEC:0001013762-24-000834:0
5,823 shares0Common StockSEC:0001213900-24-017640:1
150,000 shares0Common StockSEC:0001213900-24-017640:2
10,640 shares0Common StockSEC:0001213900-24-017640:0
79,365 shares0Common StockSEC:0001213900-24-009795:0
79,365 shares0Common StockSEC:0001213900-24-009794:0
79,365 shares0Common StockSEC:0001213900-24-009793:0
17,730 shares0Common StockSEC:0001213900-23-096070:0
63,700 shares@ US$1.5452.3% of flowCommon Stock, $0.01 Par ValueSEC:0001213900-23-074085:1
345,080 shares0Common Stock, $0.01 Par ValueSEC:0001213900-23-074085:0
5,000 shares@ US$1.290.4% of flowCommon Stock, $0.01 par valueSEC:0001290929-23-000008:1
Canonical exit: 14 May 2023 (T+90)
25 of 115 declarations
About Enzo Biochem Inc
Enzo Biochem Inc. is a U.S.-based life sciences company with a long operating history and a niche position in research tools and diagnostics. It began operations in August 1976 and is headquartered in Farmingdale, New York, United States. From a market perspective, the company was long associated with the NYSE, but in 2025 it voluntarily delisted from the NYSE and moved its common stock trading to the OTCQX market under the symbol ENZB. For investors, that change is important because it reflects both the company’s small-cap profile and the evolution of its capital-markets access. ([ir.enzo.com](https://ir.enzo.com/company-information/faq?utm_source=openai))
Today, Enzo’s core business is conducted through Enzo Life Sciences. The company focuses on labeling and detection technologies spanning DNA-based applications through whole-cell analysis. Its portfolio includes antibodies, genomic probes, assays, biochemicals, and proteins, which are used in translational research, drug discovery, drug development, cell biology, genomics, immunohistochemistry, and related scientific workflows. Enzo also highlights a sizeable intellectual-property base and a large installed scientific reputation, with more than 500 patents and a long record of peer-reviewed citations supporting its product franchise. ([enzo.com](https://www.enzo.com/about-enzo/?utm_source=openai))
Read moreShow less
In competitive terms, Enzo operates in a specialized segment of the global life-science tools market. It competes with larger diversified suppliers, but its differentiation comes from a focused catalog, internally supported manufacturing and validation, and a product set that is tailored to researchers, biotech companies, pharma customers, and diagnostic users. The company describes its Long Island campus as a hub for research and development, manufacturing, customer service, and warehouse operations, while also serving a global market through distribution channels and product sales. ([enzo.com](https://www.enzo.com/about-enzo/locations/?utm_source=openai))
Recent headlines have been shaped by corporate simplification and risk management. In March 2025, Enzo announced its intent to delist from the NYSE; the last day of NYSE trading was April 17, 2025, and OTCQX trading began on April 21, 2025. In parallel, the company disclosed progress on a class-wide settlement related to the April 2023 cyber incident, with court approval granted in June 2025. On the operating side, management emphasized new product launches, stating that approximately 100 products were launched during the third quarter of fiscal 2025, while also noting continued headwinds in life-science tools, including weaker government grant activity, reduced R&D spending, and tariff-related uncertainty. ([ir.enzo.com](https://ir.enzo.com/news-events/press-releases/detail/342/enzo-biochem-reports-third-quarter-fiscal-year-2025-results?utm_source=openai))
Overall, Enzo Biochem is best viewed as a specialized U.S. life-sciences company with a defensible technology niche, a global product footprint, and a recent history of strategic and listing-related changes that are material for equity investors. ([ir.enzo.com](https://ir.enzo.com/news-events/press-releases/detail/342/enzo-biochem-reports-third-quarter-fiscal-year-2025-results?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
